LON:AVO Advanced Oncotherapy (AVO) Share Price, News & Analysis GBX 1.75 -0.18 (-9.09%) (As of 08/30/2023) Add Compare Share Share Stock Analysis Stock Analysis About Advanced Oncotherapy Stock (LON:AVO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Advanced Oncotherapy alerts:Sign Up Key Stats Today's Range 1.75▼ 1.7550-Day Range 1.75▼ 1.7552-Week Range 1.75▼ 25.75Volume200,000 shsAverage Volume1.27 million shsMarket Capitalization£9.49 millionP/E RatioN/ADividend Yield5.49%Price TargetN/AConsensus RatingN/A Company OverviewAdvanced Oncotherapy plc, together with its subsidiaries, engages in designing, assembling, and selling proton-based radiotherapy systems for treatment of cancer. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer. The company also engages in the management of healthcare related properties. It has operations in the United Kingdom, Switzerland, and the United States. The company was formerly known as CareCapital Group plc and changed its name to Advanced Oncotherapy PLC in September 2012. Advanced Oncotherapy plc was founded in 1994 and is headquartered in London, the United Kingdom.Read More… Sell NVDA Now? (Ad)Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). Receive AVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Advanced Oncotherapy and its competitors with MarketBeat's FREE daily newsletter. Email Address AVO Stock News HeadlinesAdvanced Oncotherapy (LON:AVO) Share Price Crosses Below 200-Day Moving Average - Here's What HappenedOctober 23, 2024 | americanbankingnews.comOzarks Healthcare Partners with Avo to Integrate AI-Powered Decision Support in the EHROctober 18, 2024 | tmcnet.com625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.November 2, 2024 | Crypto Swap Profits (Ad)AVO.L Regulatory NewsAugust 23, 2024 | lse.co.ukAdvanced Oncotherapy Share ChatJanuary 23, 2024 | lse.co.ukAdvanced Oncotherapy PLC AVODecember 9, 2023 | morningstar.comFavourable Signals For Advanced Oncotherapy: Numerous Insiders Acquired StockJune 12, 2023 | finance.yahoo.comFavourable Signals For Advanced Oncotherapy: Numerous Insiders Acquired Stock \June 12, 2023 | finance.yahoo.comSee More Headlines AVO Stock Analysis - Frequently Asked Questions How have AVO shares performed this year? Advanced Oncotherapy's stock was trading at GBX 1.75 at the beginning of the year. Since then, AVO stock has increased by 0.0% and is now trading at GBX 1.75. View the best growth stocks for 2024 here. How were Advanced Oncotherapy's earnings last quarter? Advanced Oncotherapy plc (LON:AVO) released its quarterly earnings data on Monday, June, 29th. The company reported ($9.83) earnings per share for the quarter, missing the consensus estimate of ($8.90) by $0.93. How do I buy shares of Advanced Oncotherapy? Shares of AVO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Advanced Oncotherapy own? Based on aggregate information from My MarketBeat watchlists, some other companies that Advanced Oncotherapy investors own include UK Oil & Gas (UKOG), Academy Sports and Outdoors (ASO), Renishaw (RSW), Tullow Oil (TLW), BMR Group (BMR), Lancashire (LRE) and Sirius Minerals (SXX). Company Calendar Last Earnings6/29/2020Today11/02/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Medical Devices Sub-IndustryAgriculture Current SymbolLON:AVO CUSIPN/A CIKN/A Webwww.advancedoncotherapy.com Phone+44-20-36178728FaxN/AEmployees3,900Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-32,600,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-67.34% Return on Assets-11.73% Debt Debt-to-Equity Ratio98.71 Current Ratio1.26 Quick Ratio0.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 0.05 per share Price / Cash Flow33.50 Book ValueGBX 14 per share Price / Book0.13Miscellaneous Outstanding Shares542,570,000Free FloatN/AMarket Cap£9.49 million OptionableNot Optionable Beta0.06 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (LON:AVO) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Advanced Oncotherapy plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Advanced Oncotherapy With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.